- Aug 31, 2021
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
MagnetisMM-5 Relapsed Refractory Multiple Myeloma NCT05020236: Phase 3 - MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5) The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide mor
539
- Aug 31, 2021
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
EMN 29 NCT05028348: Phase 3: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma This phase 3 randomized, open-label multicenter trial will compare the efficacy
161
- Aug 30, 2021
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
PERK Inhibitor NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that a
169
- Aug 27, 2021
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years. Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, B-cell Marginal Zone Lymphoma, Non-Hodgkin Multiple Myeloma B-cell Lymphoma Waldenstrom Macroglobulinem
285
- Aug 26, 2021
Multiple Myeloma Research Foundation - MMRF - Multiple Myeloma Precursor Conditions
Multiple Myeloma Precursor Conditions: Find out the difference between monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) and what factors may put individuals with these conditions at higher risk for progressing to multiple myeloma. Multiple Myeloma Research Foundation - MMRF Multiple Myeloma Precursor Conditions | High Impact Topic (HIT) Learn more: MMRF Resources https://themmrf.org/multiple-myeloma/resources/ Multiple Myeloma Re
80
- Aug 25, 2021
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. TriPRIL CAR T Cells Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process Massachusetts General Hospital ClinicalTrials
149
- Aug 23, 2021
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
(OriCAR-017) CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS) NCT05016778: Phase 1: A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple m
536
- Aug 22, 2021
NCCN GUIDELINES FOR PATIENTS: MULTIPLE MYELOMA 2022
NCCN GUIDELINES FOR PATIENTS: MULTIPLE MYELOMA 2022 Click here to see patient's guideline book by NCCN. Presented with support from: NCCN National Comprehensive Cancer Network Foundation Guiding Treatment. Changing lives Click here to see details.
365
- Aug 21, 2021
Multiple Myeloma Research Foundation - MMRF - Minimal Residual Disease (MRD)
Multiple Myeloma Research Foundation - MMRF - Minimal Residual Disease (MRD) | High Impact Topic HIT MRD (Minimal residual disease): Learn what MRD is, how it is measured, and what it might mean if your doctor tells you that you are MRD positive or MRD negative. Multiple Myeloma Research Foundation - MMRF - Minimal Residual Disease (MRD) | High Impact Topic (HIT) Learn more: MMRF Resources https://themmrf.org/multiple-myeloma/resources/ Multiple Myeloma Research Foundation ht
114
- Aug 20, 2021
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune respo
122
- Aug 20, 2021
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9) A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9) The purpose of this study is to evaluate the safety of a st
212
- Aug 13, 2021
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 10/16/2021 - St. Louis, Missouri
MCRT Webcast - Myeloma Crowd Round Table Myeloma Crowd Round Tables program MCRT St. Louis, Missouri October 16, 2021 Personalized Treatment of Myeloma - Shaji Kumar, MD Personalized Medicine - Ravi Vij, MD Immunotherapy Treatment Strategy - Ivan Borrello, MD Immunotherapies in the Clinic - Mark Schroeder, MD Concepts of Immunotherapy - Madhav Dhodapkar, MD HealthTree Cure Hub Overview - Todd Foster Round Table Audience Q&A 1 Round Table Audience Q&A 2 Personalized Treatment
104
- Aug 12, 2021
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomal
129
- Aug 11, 2021
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647. Spo
202
- Aug 10, 2021
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
IFM2021_03 NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." (I2D IFM2021_03) Sponsor Nantes University Hospital This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relaps
92
- Aug 10, 2021
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)
Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1) A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1) Sponsor Amgen A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) o
117
- Aug 9, 2021
RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) & Dexamethasone
FDA approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) and Dexamethasone Relapsed & Refractory Multiple Myeloma FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma On July 9, 2021, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multip
434
- Aug 7, 2021
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
BelaRd Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (BelaRd) NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd) Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (BelaRd) This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in c
274
- Aug 7, 2021
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have
151